{'fraction_non_alphanumeric': 0.012429378531073447, 'fraction_numerical': 0.0, 'mean_word_length': 5.328571428571428, 'pattern_counts': {'":': 0, '<': 0, '<?xml version=': 0, '>': 0, 'https://': 0, 'lorem ipsum': 0, 'www.': 0, 'xml': 0}, 'pii_count': 0, 'substrings_counts': 0, 'word_list_counts': {'cursed_substrings.json': 0, 'profanity_word_list.json': 0, 'sexual_word_list.json': 0, 'zh_pornsignals.json': 0}}
The structure of the drug therapy prescription to cardiac patients during the primary care: the lessons of the OZIRKA study

The structure of prescriptions of cardiac drugs by the primary care physicians has remained unknown for a long time. We decided to use the data of the OZIRKA study, which aimed to investigate the effect of Ozalex (rosuvastatin) on lipid and cholesterol levels in patients with lipid metabolism disorders and hypercholesterolemia, and to assess the structure of prescriptions in real clinical practice, as well as the effectiveness of cardiovascular risk factors monitoring. We sincerely hope that the data we have obtained will optimize the treatment plan for primary care patients, improve their prognosis and survival, and provide the practitioner with evidence of the safety and efficacy of rosuvastatin that can be transferred to routine clinical practice.